Shares of Curis Inc. (NASDAQ:CRIS) traded down 3.8% during mid-day trading on Wednesday . The company traded as low as $2.18 and last traded at $2.28, with a volume of 736,596 shares traded. The stock had previously closed at $2.37.

A number of analysts recently issued reports on the company. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research report on Monday. FBR & Co restated a “buy” rating on shares of Curis in a research report on Thursday, September 8th. Finally, Robert W. Baird restated an “outperform” rating and issued a $7.00 price target on shares of Curis in a research report on Wednesday, September 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $4.56.

The firm’s market capitalization is $305.55 million. The firm has a 50 day moving average of $1.80 and a 200-day moving average of $1.74.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.09). The business earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The business’s revenue was down 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) earnings per share. Analysts predict that Curis Inc. will post ($0.38) EPS for the current year.

In other news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the transaction, the insider now owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.09% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of CRIS. Barclays PLC boosted its stake in shares of Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Curis during the second quarter valued at approximately $146,000. ProShare Advisors LLC boosted its stake in shares of Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Curis during the first quarter valued at approximately $248,000. Hedge funds and other institutional investors own 52.36% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.